Vifor Pharma has strong partnerships with:
Strategic Partnerships with Fresenius Medical Care
To strengthen its position in the global intravenousiron market, in 2009 Vifor Pharma entered into its first strategic partnership with Fresenius Medical Care, the world leader in dialysis products and services. The exclusive licence agreement included the commercialisation of Venofer® (iron sucrose) and Ferinject® (iron carboxymaltose) for iron deficiency and iron deficiency anaemia in haemodialysis in US, Europe, the Middle East, Africa and Latin America.
In December 2010 Vifor Pharma and Fresenius Medical Care announced an extension of their partnership through the creation of a specialty pharmaceuticals company. Vifor Fresenius Medical Care Renal Pharma Ltd., will develop and commercialise innovative and high quality products to improve the lives of patients suffering from chronic kidney disease (CKD) worldwide.
The products of Vifor Fresenius Medical Care Renal Pharma Ltd. include Venofer® and Ferinject® (Injectafer®, the brand name for Ferinject® in the USA) in the field of dialysis and pre-dialysis (CKD stage III – V) as well as Velphoro®, a novel iron-based phosphate binder.
Vifor Pharma contributes its expertise in phosphate binding and its global leadership in iron replacement therapy. FMC provides access to its network of dialysis centres, which is the most extensive in the world.
Luitpold & Fresenius Medical Care partner in the USA
Since 2008 Luitpold Pharmaceuticals, Inc., has held an exclusive licence to market Venofer® and Injectafer® (the product is currently in the approval process) in the US and Canada. For these markets Luitpold Pharmaceuticals, Inc., and Vifor Pharma have also entered into an agreement with Fresenius Medical Care with an exclusive US distribution sub-licence for Venofer® in the field of haemodialysis.
Nycomed (a Takeda Company) partnership around the world
In June 2010 Nycomed and Vifor Pharma, signed a distribution agreement that includes intravenous iron products. Nycomed is the exclusive distributor of Venofer® and Ferinject® in Russia-CIS.
Further agreements are in place in Argentina, Brasil, Greece, Mexico and in South Africa.
Abdi İbrahim partner in Turkey
Abdi İbrahim is one of the largest pharmaceutical companies in Turkey, and represents the Vifor Pharma product portfolio with a dedicated sales force. The two companies have a long history of partnership.
Kissei & Fresenius Medical Care Partners for Velphoro® (iron based phosphate binder)
In September 2010 Vifor Pharma agreed with Kissei Pharmaceutical Co. Ltd. to develop and commercialise its novel iron-based phosphate binder – Velphoro® – in Japan. Kissei Pharmaceutical Co Ltd. is one of Japan's leading specialty pharmaceutical companies. This collaboration is a further step in the strategy of developing and commercialising Velphoro® with strong regional partners. Already in June 2010 the partnership with Fresenius Medical care for the US was announced and further extended in December 2010 through the creation of the specialty pharma company Vifor Fresenius Medical Care Renal Pharma Ltd. Vifor Pharma contributes with its expertise in phosphate binding whereas FMC provides access to its network of dialysis centers. This collaboration supports the implementation of the Velphoro® phase III clinical study in the US and the commercialization of Velphoro® in US and Europe.
Collaboration with Roche for CellCept®
Vifor Pharma continues its successful collaboration with Hoffmann-La Roche (Roche). The goal of the collaboration is to explore the potential clinical use of Roche’s immunosuppressant CellCept®, approved for use in transplantation, in three rare autoimmune indications.
While the clinical studies for pemphigus vulgaris and myasthenia gravis did not reach their statistical endpoints, CellCept® showed clinical benefit in particular for patients with SLE. In the Aspreva Lupus Management Study (ALMS) trial, the largest clinical trial conducted so far in patients with lupus nephritis, the induction phase of the study did not achieve its statistical end point. However, the maintenance phase of the study was successful in demonstrating the superiority of CellCept® versus azathioprine in delaying treatment failure in patients with lupus nephritis. This positive outcome concludes the current development program. The study results are being presented at medical congresses and were published in the prestigious New England Journal of Medicine (NEJM) in November 2011.